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Abstract
Lung cancer is the leading cause of cancer-related death in the world. Non-small cell lung carcinomas (Non-SCLC) account
for almost 80% of lung cancers, of which 40% were adenocarcinomas. For a better understanding of the molecular
mechanisms behind the development and progression of lung cancer, particularly lung adenocarcinoma, we have used
proteomics technology to search for candidate prognostic and therapeutic targets in pulmonary adenocarcinoma. The
protein profile changes between human pulmonary adenocarcinoma tissue and paired surrounding normal tissue were
analyzed using two-dimensional polyacrylamide gel electrophoresis (2-DE) based approach. Differentially expressed protein-
spots were identified with ESI-Q-TOF MS/MS instruments. As a result, thirty two differentially expressed proteins (over 2-fold,
p,0.05) were identified in pulmonary adenocarcinoma compared to normal tissues. Among them, two proteins (PKM2 and
cofilin-1), significantly up-regulated in adenocarcinoma, were selected for detailed analysis. Immunohistochemical
examination indicated that enhanced expression of PKM2 and cofilin-1 were correlated with the severity of epithelial
dysplasia, as well as a relatively poor prognosis. Knockdown of PKM2 expression by RNA interference led to a significant
suppression of cell growth and induction of apoptosis in pulmonary adenocarcinoma SPC-A1 cells in vitro, and tumor
growth inhibition in vivo xenograft model (P,0.05). In addition, the shRNA expressing plasmid targeting cofilin-1
significantly inhibited tumor metastases and prolonged survival in LL/2 metastatic model. While additional works are
needed to elucidate the biological significance and molecular mechanisms of these altered proteins identified in this study,
PKM2 and cofilin-1 may serve as potential diagnostic and prognostic biomarkers, as well as therapeutic targets for
pulmonary adenocarcinoma.
Citation: Peng X-c, Gong F-m, Zhao Y-w, Zhou L-x, Xie Y-w, et al. (2011) Comparative Proteomic Approach Identifies Pkm2 and Cofilin-1 as Potential Diagnostic,
Prognostic and Therapeutic Targets for Pulmonary Adenocarcinoma. PLoS ONE 6(11): e27309. doi:10.1371/journal.pone.0027309
Editor: Emanuele Buratti, International Centre for Genetic Engineering and Biotechnology, Italy
Received July 4, 2011; Accepted October 13, 2011; Published November 8, 2011
Copyright:  2011 Peng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding is gratefully acknowledged from the National Natural Sciences Foundation of China (30900768). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: aipingtong@gmail.com
. These authors contributed equally to this work.
Introduction
Lung cancer was a leading cause of cancer-related death and
the 5-year overall survival rate was below 16% [1]. According
to the WHO’s estimation, China will become one of the
countries that have a relatively high incidence of lung cancer in
the 21st century [2]. Non-small cell lung carcinomas (Non-
SCLC) account for almost 80% of lung cancers, of which 40%
were adenocarcinomas. Early detection can increase the
chances of the patient responding well to treatment, which
was evidenced by the effect that 63% of the patients with early
stages had an expected five-year survival [3]. Thus, it is no
doubt that discovering biomarkers used for the early detection
of lung adenocarcinomas and the monitoring of disease
progression is very critical. And the identification of novel
therapeutic targets would also facilitate drug development for
lung adenocarcinomas.
The development of genome-wide screening have displayed that
the initiation, development and outcome of lung adenocarcinomas
was associated with DNA methylation [4,5], some genetic
mutations, such as K-ras [6,7], p53 [8] and EGFR [9], as well
as altered expression of genes, such as VEGF, S100P and crk [10].
These novel biomarkers have been utilized in the diagnosis,
prognosis prediction and treatment of lung cancer. However,
mRNA expression does not necessarily correlate with protein level,
and posttranslational modifications, such as phosphorylation, can
not be predicted from transcription assay result [11]. So it is
thought that analysis of the cancer proteome can be more
informative than genomics alone [12].
The proteomic approach has resulted in many opportunities
and challenges in identifying new tumor markers and therapeutic
targets, and in understanding disease pathogenesis [13]. Previous
studies have performed the preliminary application of 2-DE in the
identification of the biomarkers for lung adenocarcinoma, which
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number of proteins, including some metabolic enzymes, signal
transduction proteins, oncoproteins and so on [3,14]. To date,
however, few molecular biomarkers for lung adenocarcinoma have
been introduced into clinical practice, mainly owing to insufficient
validation and the absence of prospective studies. Moreover, few
studies have been functionally analyzed for their roles in
carcinogenesis, and therefore there is a lack of the fundamental
understanding required for clinical applications and a need for a
better comprehension of the underlying biological processes
[15,16]. Finally, the previous study population mainly consists of
Caucasian while only a few proteomic studies on lung adenocar-
cinoma of Asian population have been reported [3,14]. The ethnic
differences among patients may contribute to different findings
and conclusions.
In the present study, we utilized a 2-DE based proteomic
approach to profile the altered proteins between lung adenocar-
cinoma tissues and corresponding normal lung tissues. Of the
identified thirty two dysregulated proteins, two significantly
upregulated proteins (PKM2 and cofilin-1) were further studied
in the thoughts of their important biological functions. The data
presented in this study suggested that both PKM2 and cofilin-1
could be developed as valuable prognostic factors, as well as
potential therapeutic targets for lung adenocarcinoma.
Materials and Methods
Ethics Statement
Tissue samples and patient data were obtained with informed
written consent. The project was approved by the Scientific and
Ethical Committee of Sichuan University, China (NO. 090563).
Tissue specimens
All tissue samples were obtained from West China Hospital,
Sichuan University. Samples were examined histologically after
staining with H&E staining, and clinicopathologic stage was
determined according to the TNM classification system of the
International Union against Cancer. Lung adenocarcinoma tissues
and corresponding normal tissues were collected from 9 lung
adenocarcinoma patients (Table 1). Tumor tissues were incised
from the center of tumor mass, and the paired corresponding
normal tissues were incised along a surgically called safety border
which was verified with frozen section staining. All the tissue
specimens were snap-frozen in liquid nitrogen for proteomic
analysis. For immunohistochemistry (IHC) analyses, tissue speci-
mens were recruited from the archives of the pathology
department of West China hospital. All clinical information was
obtained from archives of case history. Informed consent was
obtained from all of patients or their relatives for the use of their
tissues in the experimental procedures.
2-DE and image analysis
Tissues were ground into powder in liquid nitrogen and lysed in
lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 100 mM DTT,
0.2% pH 3–10 ampholyte, Bio-Rad, USA) containing protease
inhibitor cocktail 8340 (Sigma, St. Louis, MO). After centrifuga-
tion followed by vortex and incubation, supernatant was
precipitated with cold actone. The pellet was redissolved in the
lysis buffer. The protein concentrations were determined using DC
protein assay kit (Bio-Rad). Protein samples (2 mg) were applied to
IPG strip (17 cm, pH 3–10 NL, Bio-Rad) using a passive
rehydration method. After 12–16 h of rehydration, the strips were
transferred to an IEF Cell (Bio- Rad). IEF was performed as
follows: 250 V for 30 min, linear; 1000 V for 1 h, rapid; linear
ramping to 10 000 V for 5 h and finally 10 000 V for 4 h. Second
dimension was performed using 12% SDS-PAGE at 30 mA
constant current per gel after equilibration. Gels were stained
using CBB R-250 (Merck, Germany) and scanned with a Bio-Rad
GS-800 scanner. Pooled samples were prepared by mixing the 9
clinical samples with equal amount. Three independent runs were
made for the pooled samples to ensure the accuracy of analyses.
The maps were analyzed by PDQuest software Version 6.1 (Bio-
Rad). The quantity of each spot in a gel was normalized as a
percentage of the total quantity of all spots in that gel and
evaluated in terms of OD. For statistical analysis, paired t-test was
performed to compare data from the three repeated experiments.
Only spots that showed consistent and significant differences
(6over twofold, p,0.05) were selected for analysis with MS.
In-gel digestion
In-gel digestion of proteins was carried out using MS-grade
Trypsin Gold (Promega, Madison, WI) according to the
manufacturer’s instructions. Briefly, spots were cut out of the gel
(1–2 mm diameter) using a razor blade, and destained twice with
100 mM NH4HCO3/50% ACN at 37uC for 45 min in each
treatment. After drying, the gels were preincubated in 10–20 ml
trypsin solution for 1 h. Then, 15 ml digestion buffer was added
(40 mM NH4HCO3/10% ACN) to cover each gel and incubated
overnight at 37uC. Tryptic digests were extracted using MilliQ
water initially, followed by two times extraction with 50% ACN/
5% TFA for 1 h each time. The combined extracts were dried in a
vacuum concentrator at room temperature. The samples were
then subjected to MS analysis.
ESI-Q-TOF analysis and protein identification
Mass spectra were acquired using a Q-TOF mass spectrometer
(Micromass, Manchester, UK) fitted with an ESI source (Waters).
Tryptic digests were dissolved in 18 ml 50% ACN. For ESI-Q-
TOF analysis, the automatic scan rate was 1.0 s with an inter-scan
delay of 0.02 s, and the system was operated at 3.0 kV. Spectra
were accumulated until a satisfactory S/N had been obtained.
Parent mass peaks with the range from 400 to 1600 m/z were
picked out for MS/MS analysis. The collision energy was chosen
to vary between 18 and 57 eV depending on the mass of the
precursor. The MS/MS data were acquired and processed using
MassLynx V 4.1 software (Micromass) and were converted to PKL
files by the ProteinLynx 2.2.5 software (Waters). The PKL files
were analyzed using the MASCOT search engine (http://www.
matrixscience.com). Database searches were carried out using the
following parameters: Database, Swiss-Prot; taxonomy, homo
sapiens; enzyme, trypsin; mass tolerance, 60.1 Da; MS/MS
tolerance, 60.05 Da; and an allowance of one missed cleavage.
Fixed modifications of cysteine carboamidomethylation, and
variable modifications of methionine oxidation were allowed.
The data format was selected as Micromass PKL and the
instrument was selected as ESI-Q-TOF. Proteins with probability
based MOWSE scores, derived from ions scores as a non-
probabilistic basis for ranking protein hits when using Mascot
searching engine, exceeding their threshold (p,0.05), and with the
molecular weight and pI consistent with the gel regions from
which the spots were excised, were considered to be positively
identified.
Western blotting
Proteins were extracted in RIPA buffer (50 mM Tris-base,
1.0 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Triton X-100,
1% Sodium deoxycholate, 1 mM PMSF) and quantified by the
DC protein assay kit (Bio-Rad). Samples were separated by 12%
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Biosciences). After blocking with 5% non-fat milk in Tris-buffered
saline (TBS), 0.1% Tween 20 for 1 h, membranes were incubated
overnight at 4uC with respective primary antibodies. Specific
primary antibodies performed included rabbit anti-human cofilin-
1 antibody (Abcam, Cambridge, UK), and rabbit anti-human
PKM2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
After that, the blots were incubated with secondary antibody
conjugated to HRP for 2 h at room temperature. Target proteins
were detected by enhanced chemiluminescence reagents (Amer-
sham Pharmacia Biotech, Piscataway, USA). A monoclonal anti-
b-actin antibody (Sigma) was used as a loading control.
Immunohistochemistry and Correlation Analysis
Sections were stained by Envision System-HRP method (Dako-
Cytomation Inc, Carpinteria, CA), according to kit manufacturer’s
instructions. Specific antibodies performed included rabbit anti-
human cofilin-1 antibody(Abcam, Cambridge, UK), rabbit anti-
human PKM2 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) and rabbit anti-human PCNA antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA). Saturation and intensity of immunostained
cells was evaluated over 8 visual fields at a power of 6400 under a
light microscope (Olympus Optical, Tokyo, Japan). In statistical
analysis, with reference to Jeffrey’s study [17], total staining of PKM2
or cofilin-1 were scored as the product of the staining intensity (on a
scale of 0–3: negative=0, weak=1, moderate=2, strong=3) 6the
percentage of cells stained (positively recorded on an ordered
categorical scale: 0 = zero, 1=1–25%, 2 = 26–50%, 3=51–
100%), which resulted in a scale of 0–9. The evaluation was
performed by two independent investigators, without any prior
knowledge of each patient’s clinical information and outcome. Any
discrepancy between the two evaluators was resolved by reevaluation
and careful discussion until agreement was reached. In correlation
analysis, the survival data of patients were classified as weak (0–3),
moderate (3.1–6), or strong (6.1–9) staining of PKM2 or cofilin-1 or
both biomarkers. Multivariate analyses were carried out using Cox
proportional hazard model.
Short hairpin RNA construction and production
ShRNA with the sequence 59-CCGGGCTGTGGCTCTAGA-
CACTAAACTCGAGTTTAGTGTCTAGAGCCACAGCTTT-
TTG-39was used to inhibit the expression of PKM2 as described
previously [18]. According to the previous study [19], the shRNA
with the sequence 59-GGATCCCGAGCGGACATTTAGGAA-
CTTTCAAGAGAAGTTCCTAAATGTCCGCTCTTTTTTC-
CAAAAGCTTT-39was used to inhibit the expression of cofilin-1.
HK sequence, which has no homology with any mammalian
sequence, was used as negative control. Eukaryotic expression
vector pGenesil-2 (Genesil Biotechnology, Wuhan, China) was
used to construct the shRNA expressing plasmid. Plasmids were
extracted using a Qiagen Plasmid Mega Kit (Qiagen, Hilden,
Germany) and stored at 220uC.
Liposome preparation
DOTAP:chol liposome was prepared using the procedure
described previously [20]. Briefly, cationic lipid DOTAP was
mixed with neutral lipid Chol at equimolar concentrations. Mixed
lipids were dissolved in chloroform in a 100 ml-round-bottomed
flask. Then, clear solution was rotated on a Buchi rotary
evaporator at 30uC for 30 min to make a thin film, and the flask
containing thin lipid film was dried under vacuum for 15 min. The
film was hydrated in 5% dextrose in water (D5W) to give a final
concentration of 7 mM DOTAP and 7 mM chol, referred to as
7 mM DOTAP:chol. The hydrated lipid film was rotated in a
water bath at 50uC for 45 min and then 35uC for 10 min. The
mixture was allowed to stand in the parafilm-covered flask at room
temperature overnight, after which the mixture was sonicated at
low frequency for 5 min at 50uC, transferred to a tube, and heated
for 10 min at 50uC. The mixture was sequentially extruded
through Millipore (Billerica, MA) polycarbonate membrane of
decreasing size: 0.2 mm for 5 times and 0.1 mm for 3 times using
syringes. Liposomes were stored under argon gas at 4uC. DOTAP
was purchased from Avanti Polar Lipids (Alabaster, AL), and
highly purified Chol was purchased from Sigma (St. Louis, MO).
Cell culture and transfection
Human lung adenocarcinoma cells SPC-A1 and murine Lewis
lung carcinoma cell line LL/2 were obtained from American Type
Culture Collection. Cells were maintained in RPMI 1640 or
DMEM (Life Technologies) containing 10% FBS (Life Technolo-
gies), 100 units/ml penicillin (Thermo) and 100 units/ml Strepto-
mycin (Thermo).Cells were grown ina 5%CO2incubatorat 37uC.
Cells were grown on a 6-well plate in growth medium until they
reached 70% confluence. Liposomes and plasmids were diluted in
antibiotics and serum-free media, respectively, and then combined
at a ratio of 2.5:1(5 mg liposome/2 mg DNA). The combinations
were transfected to the cells according to previous studies [20].
The quantitative assessment of apoptosis
Harvested cells were stained with 1 ml hypotonic fluorochrome
solution containing 50 mg/ml propidium iodide in 0.1% sodium
Table 1. The clinical and pathologic data of patients with lung adenocarcinoma for 2-DE.
Sample No Gender Age (year) Histological type TNM classification Clinical stage
1 Male 49 Well diff. T2bN0M0 II a
2 Male 67 Mod diff. T2bN1M0 II b
3 Female 52 Poor diff. T2aN0M0 I b
4 Female 38 Poor diff. T3N1M0 III a
5 Male 55 Mod diff. T1N1M0 II a
6 Female 44 Poor diff. T3N0M0 II b
7 Female 63 Well diff. T2aN0M0 I b
8 Male 59 Poor diff. T3N1M0 III a
9 Female 64 Mod diff. T1N1M0 II a
doi:10.1371/journal.pone.0027309.t001
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were performed to identify apoptotic cells and to measure the
percentage of sub-G1 cells using a flow cytometer (ESP Elite;
Coulter).
Colony Formation assay
Cells transfected with ShRNA complexed with liposome were
seeded at 2610
2 per well and allowed to grow for an additional 14
days. The colonies were then fixed with methanol and stained with
Crystal Violet (Sigma, St Louis, MO) and counted under a
microscope.
Therapy in SPC-A1 xenograft tumor model
Female nude BALB/c mice of 6 to 8 weeks old were purchased
from experimental animal center of Sichuan University (Chengdu,
Sichuan province, China) and were housed in our animal research
facility. Mice were kept in groups of five per cage and fed with
clean food and water. Animals were acclimatized for 1 week before
use and maintained throughout at standard conditions: 2462uC
temperature, 50610% relative humidity.
Female BALB/C nude mice were challenged subcutaneously
with 5610
6 SPC-A1 tumor cells per mouse in right flank. After 8
days, when the tumor diameters were about 0.6–0.8 cm, the
tumor-bearing mice were randomly assigned into the following
four groups and each mouse received the corresponding treatment
by caudal vein injection: (a) PBS group, 100 ml of PBS; (b) Lipo
group, liposome 25 mg (volume=100 ml); (c) Negative control (NC
group), pGenesil-2-HK-shRNA 10 mg complexed with liposome
25 mg (volume=100 ml); (d) ShRNA group, pGenesil-2-PKM2-
shRNA 10 mg complexed with liposome 25 mg (volume=100 ml).
Injections were performed every three days, and tumor volumes
were evaluated according to the following formula: tumor volume
(mm
3) = 0.526length6width
2. Side effects of treatment and the
weight, appetite, and behavior of the mice were recorded for 27
days, after which the mice were sacrificed.
Tumor net weight of each mouse was measured. The dissected
tumors were fixed in neutral buffered formalin and embedded in
paraffin, and sections (5 mm) were used for histologic analysis.
TUNEL assay
Presence of apoptotic cells within tumor sections was evaluated
by TUNEL (terminal deoxynucleotidyltransferase-mediated
dUTP nick-end labeling) technique using the DeadEnd Fluoro-
metric TUNEL System (Promega, Madison, WI) following the
manufacturer’s protocol. Percent apoptosis was determined by
counting the number of apoptotic cells and divided by the total
number of cells in the field (5 high power fields/slide).
Therapy in lung metastatic model
Female C57BL/6 mice (6–8 weeks old) were purchased from
experimental animal center of Sichuan University (Chengdu,
Sichuan province, China) and were housed in our animal research
facility. Each mouse was inoculated with LL/2 cells (5 610
5) via
the tail vein to establish lung metastatic model. These lung
metastatic mice were randomly assigned into the following four
groups at day 12 and each mouse received the corresponding
treatment by caudal vein injection: (a) PBS group, 100 ml of PBS;
(b) Lipo group, liposome 25 mg (volume=100 ml); (c) Negative
control (NC group), pGenesil-2-HK-shRNA 10 mg complexed
with liposome 25 mg (volume=100 ml); (d) ShRNA group,
pGenesil-2-cofilin-1-shRNA 10 mg complexed with liposome
25 mg (volume=100 ml). Caudal vein injections were performed
every three days. After 6 mice from each group were sacrificed at
day 30, lung net weight of each mouse was measured. Autopsy was
performed to determine the number of the metastatic nodules of
lung. The other mice (eight mice/group) were followed for survival
time.
Toxicity assessment
Normal human bronchial epithelial cells BEAS-2B were
obtained from American Type Culture Collection. Colony
Formation assays were conducted as mentioned above. We also
conducted an in vivo study of the effects of PKM2 or cofilin-1-
ShRNA on the lung weight of tumor non-bearing mice to check
for non-specific effects. Tumor non-bearing mice were randomly
assigned into the following four groups and each mouse received
the corresponding treatment by caudal vein injection: (a) PBS
group, 100 ml of PBS; (b) Lipo group, liposome 25 mg (volu-
me=100 ml); (c) Negative control (NC group), pGenesil-2-HK-
shRNA 10 mg complexed with liposome 25 mg (volume=100 ml);
(d) PKM2 or cofilin-1-ShRNA group, shRNA 10 mg complexed
with liposome 25 mg (volume=100 ml). When treatments were
finished, mice were sacrificed, and lung were harvested, weighed
and fixed in 4% formaldehyde solution. Tissues were then
sectioned, stained with H&E, and observed by two pathologists
in a blinded manner.
Statistical analysis
Paired t-test and one way ANOVA was used to analyze
differences between groups. Survival curves were generated
according to the Kaplan-Meier method and the statistical analyses
were performed using Log-rank test. Relevance analysis of ordinal
data was performed by cross X
2 test. P,0.05 was considered
significant in all analyses.
Results
2-DE and ESI-Q-TOF-MS/MS analysis
2-DE analysis for pooled tumor and normal tissues from 9
patients (Table 1) were independently repeated for three times. A
pair of representative 2-DE maps was shown in Fig. 1A. A total of
32 unique proteins were positively identified by ESI-Q-TOF-MS/
MS (arrows in Fig. 1A and listed in Table S1). Cluster Analysis
revealed that the altered proteins were involved in diverse
biological processes, including metabolism (40.6%), electron
transport/redox regulation (18.8%), immune response (9.4%)
and so on (Fig. 1B). Among them, both PKM2 and cofilin-1 were
identified with significant alterations. PKM2 was up-regulated 2.9-
fold and cofilin-1 was up-regulated 3.7-fold in tumor compared to
paired surrounding normal tissue (p,0.05). The two proteins were
selected as examples showing ESI-Q-TOF-MS/MS analysis
(Fig. 2). As shown, PKM2 was positively identified with 18
matched peptides and a MOWSE score of 250 and cofilin-1 with
15 matched peptides and a MOWSE score of 280.
Western blot validation and IHC analysis
As shown in Fig. 2 C, F, overexpression of PKM2 or cofilin-1
was observed in pooled carcinoma samples compared with
corresponding adjacent normal samples when subjected to western
blot assays, which was consistent with the observation made in 2-
DE analysis. To further study the potential oncogenic properties of
PKM2 and cofilin-1, and to assess their potential prognostic and
therapeutic value, IHC was performed to examine PKM2 and
cofilin-1 expression in 98 paraffin-embedded tissues. As shown in
Table 2 and Fig. 3 A, of the 30 adjacent normal tissues, positive
staining of PKM2 was rarely detected and total staining score was
only 0.8061.47. However, the other three groups, including well
Proteomic Analysis of Pulmonary Adenocarcinoma
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27309differentiated, moderately differentiated and poorly differentiated,
showed a remarkable increasing trend of positive staining of
PKM2, with 1.8661.56, 3.4162.40, 7.1861.65 total staining
score, respectively. Moreover, similar trend was found in IHC
staining of cofilin-1 (Table 3 and Fig. 3 A). These result indicated
that increased expression of PKM2 and cofilin-1 were paralleled
with increasing severity of epithelial dysplasia (Fig. 3 A).
To assess the correlation between overexpression of PKM2 or
cofilin-1 and patient survival rate, 98 patients were retrospectively
studied. As shown, when PKM2 was assessed as a single marker,
the five year survival rates were 55%, 34%, 18% for weak,
moderate and strong staining samples, respectively (Fig. 3 B). And
the five year survival rates were 48%, 39%, 28% for weak,
moderate and strong staining samples, respectively, when cofilin-1
was assessed as a single marker (Fig. 3 C). Multivariate analyses
using Cox proportional hazard model showed that both PKM2
and cofilin-1 could be developed as an independent prognostic
factor for lung adenocarcinoma. At last, the combination of
PKM2 and cofilin-1 as predictors for survival were also tested. The
5-year overall survival rate for the PKM2-/cofilin-1- strongly
positive group was very poor (0%), compared with the other two
groups (Fig. 3 D), suggesting combination of the two markers may
facilitate a more accurate prognosis of lung adenocarcinoma.
Clonogenic formation assay and apoptosis assay
To study the potential tumorigenesis function of PKM2, human
lung adenocarcinoma cell line SPC-A1 was treated with PKM2-
ShRNA. As shown in Fig. 4A, SPC-A1 cells have an obvious sub-
G1 peak (34%) compared with control groups after treatment with
PKM2-ShRNA plasmids for 48 h by flow cytometry assay.
Clonogenic formation assays demonstrated that upon 14-day
continuous culture, the clone numbers were 237624.78,
224621.61, and 216614.09 in PBS group, Lipo group, and NC
group, respectively (Fig. 4B, C). Meanwhile the clone number in
the PKM2-ShRNA treated group was 8369.43 with an inhibition
ratio of 64.9% (Dunnett’s t test, p,0.01) (Fig. 4B, C). Expression
Figure 1. Protein profiles between lung adenocarcinoma tissues and corresponding normal lung tissues. (A). Representative 2-DE
maps of lung adenocarcinoma and normal tissues, with 2 mg protein loading amount and visualized by Coomassie blue staining. Arrows indicate
identified protein spots significantly and consistently altered between carcinoma tissue and control normal tissues. (B). Cluster analysis, the altered
proteins were involved in diverse biological processes, including metabolism (40.6%), electron transport/redox regulation (18.8%), immune response
(9.4%), proteolysis (6.3%), and so on.
doi:10.1371/journal.pone.0027309.g001
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ShRNA transfection (Fig. 4D).
Anti-tumor effects of PKM2-ShRNA plasmids in vivo
As shown in Fig 5A, treatment with PKM2-ShRNA plasmids
resulted in primary tumor growth regression of 57.3%, 54.7% and
52.9% when compared with PBS, Lipo and NC groups
respectively (P,0.05). The average weight of the tumors in
PKM2-ShRNA plasmids treated group was reduced by 54%,
53.5% and 49.4% when compared with PBS, Lipo and NC groups
respectively (P,0.05). To obtain additional insight into the in vivo
effects, tumor cell apoptosis and proliferation were assessed by
TUNEL assay and PCNA immunoreactivity analysis. Fig.5 B & C
showed a significantly greater percentage of TUNEL-positive
nuclei in PKM2-ShRNA group than control groups treated with
PBS, Lipo, or NC (49.966.07 versus 4.562.76, 9.364.37, or
11.565.74, Dunnett-t test, P,0.01). In contrast, percentages of
PCNA-positive nuclei in control groups reached 97.863.62,
94.965.06, 89.368.64 for PBS, Lipo, and NC group respectively,
whereas corresponding values for PKM2-ShRNA-treated group
reached only 41.567.91, which was on average over 57% smaller
than PBS control (Student’s t test, P,0.01).
Cofilin-1 silencing Reduced metastatic nodules and
prolonged survival in pulmonary metastatic mouse
model
The in vivo antitumor effects of cofilin-1-ShRNA complexed
with cationic liposome (DOTAP/Chol) were evaluated in terms of
pulmonary metastatic tumor growth and survival in mice. As
shown in Figure 6 A, the tumor nodules were significantly reduced
in cofilin-1-ShRNA -treated mice. The average lung weight of
mice treated with cofilin-1-ShRNA was 61.2%, 56.8% and 53.7%
less than that treated with PBS, Lipo and NC respectively
(P,0.05, Figure 6 B). More importantly, treatment of cofilin-1-
ShRNA exhibited a significant prolongation of survival compared
to control mice (P,0.01, Figure 6 C).
Toxicity assessment
Treatment with PKM2 or cofilin-1-ShRNA did not affect the
growth of normal human bronchial epithelial cells BEAS-2B by
clonogenic formation assay (P.0.05, Figure 6 D). In vivo studies
also showed that the lung weight from PKM2 or cofilin-1-ShRNA
treated group (normal mice, i.e. not bearing tumor) did not have
significant changes compared with control groups (P.0.05,
Figure 6 E). Furthermore, no toxic pathological changes in lung
were found via microscopic examination (data not shown).
Discussion
As one of the most common malignancies worldwide, lung
adenocarcinoma remains a major health problem with increasing
incidence rates even to date [1,21]. Thus, there is an urgent need
to identify novel molecular targets for diagnosis, prognosis and
treatment of lung adenocarcinoma. In the present study, the global
protein profiles were compared between lung adenocarcinoma
tissues and corresponding normal lung tissues using a 2-DE and
MS/MS-based approach. A total of 32 differentially expressed
proteins were identified and cluster analysis revealed that these
altered proteins were involved in diverse biological processes,
mainly including metabolism (40.6%), electron transport/redox
regulation (18.8%), immune response (9.4%), and proteolysis
(6.3%).
Among these identified proteins, NME1 gene, also called
Nm23, is the first of 13 identified tumor metastasis suppressor
genes [22,23]. NME1 was shown to be decreased 2.2-fold in lung
adenocarcinoma in the present study. NME1, a member of the
Figure 2. ESI-Q-TOF MS/MS identification and western blot validation of representative proteins PKM2 and cofilin-1. (A&D ). Mass
spectrogram of tryptic peptides of PKM2 and cofilin-1. (B&E ). Protein sequence of PKM2 and cofilin-1. The matched peptides are underlined. (C&F ).
Western blot validation of PKM2 and cofilin-1 with pooled clinical samples. N: normal tissues; C: lung adenocarcinoma tissue.
doi:10.1371/journal.pone.0027309.g002
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multiple biochemical functions, including interactions with
numerous proteins with nucleoside diphosphate kinase activity
and histidine protein kinase activity [24]. The overexpression of
NME1 contributes to reduced anchorage-independent coloniza-
tion, inhibited invasion and motility in response to multiple
factors, and up-regulated differentiation in in vitro assays [25,26].
Decreased NME1 protein in tumor samples is correlated with
characteristics of aggressive cancer, such as poor clinical survival
and prognosis, lymph node infiltration, as well as invasiveness and
metastasis in a variety of tumor types, including breast, lung,
melanoma, gastric, ovarian, cervical, and hepatocellular carcino-
mas [27]. Another interesting altered gene was fumarate hydratase
(FH), a key enzyme in tricarboxylic acid cycle. It had been
reported that individuals with loss of FH activity are at risk for the
development of leiomyomas of the skin and uterus (fibroids) as well
as kidney cancer [28,29,30]. Genetic analysis of tumor samples
indicates that FH acts as a tumor suppressor gene [30]. FH was
shown to be decreased 3.4-fold in lung adenocarcinoma in the
present study.
There are several dramatically changed proteins (N/A, Table
S1) which were potentially related to lung cancer genesis. For
example, apolipoprotein A-1 was found downregulated in
pulmonary adenocarcinoma by 2-DE coupled to MALDI-TOF
peptide mass fingerprinting and was presently recognized as a new
biomarker for pulmonary adenocarcinoma [31]. Overexpression
of Voltage-dependent anion-selective channel protein 1 (VDAC1)
predicts shorter time to recurrence and overall survival for non-
Table 2. PKM2 immunostaining results of patients with lung adenocarcinoma.
Tissue type Number Male Female Positive rate Intensity Total staining Score
a,
Adjacent normal tissues 30 14 16 0.4760.68 0.5760.86 0.8061.47
Well 21 11 10 1.4360.87 1.0560.59 1.8661.56
Moderately 37 16 21 1.7360.96 1.7660.93 3.4162.40
Poorly 40 19 21 2.7560.44 2.6360.49 7.1861.65
a: Total staining of PKM2 was scored as the product of the staining intensity (on a scale of 0–3) 6the percentage of cells stained (on a scale of 0–3).
doi:10.1371/journal.pone.0027309.t002
Figure 3. Immunohistochemical (IHC) analysis. (A). IHC staining against PKM2 and cofilin-1. (B). Kaplan-Meier survival curves showed the
correlation between higher levels of PKM2 expression and lower survival rates (p,0.05). (C). Kaplan-Meier survival curves showed the correlation
between higher levels of cofilin-1 expression and lower survival rates (p,0.05). (D). Kaplan-Meier survival curves showed the combination of PKM2
and cofilin-1 as predictor correlated more closely with prognosis of lung adenocarcinoma (p,0.05).
doi:10.1371/journal.pone.0027309.g003
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composed of both cancer cells and stromal cells recruited from
normal tissue, such as fibroblastic cells, endothelial cells, and cells
of hematopoietic origin. At the late-stage, the interactions between
stromal cells and tumor cells often result in histologic vascular
thrombosis and tumor necrosis. So some of the factors identified as
differentially expressed in the present study were not directly
related to tumor cell development. And some of these proteins
were also reported by other proteomic studies previously. For
example, fibrinogen gamma were found to be over-expressed in
pancreatic cancer [33], some coagulation factors were reported to
be candidate cancer biomarkers [34], and coagulation factor VII
even can be secreted by cancer cell themselves [35]. Due to post-
translational modification, isoform, amino acid composition,
hydrophobicity, three dimensional structure and so on, in 2-DE,
it happens very often that several adjacent spots were identified by
MS to be the same protein. For instance, spot 12 in figure 1 is
likely to be a phosphorylated isoform of fibrinogen gamma
[33,36]. Further study of the molecular mechanism of these
changed proteins in cancer genesis will help us find new diagnostic
and therapeutic approaches for lung cancer.
Pyruvate kinase (PK), one of the key glycolytic enzymes, has
four isoforms in mammals, M1, M2, L, and R that are
differentially expressed in different cell types [37]. The original
tissue specific pyruvate kinase (i.e., type L, R, and M1) is replaced
by PKM2 during tumorigenesis. Previously studies had implied
that this change could help tumor cells to produce lactic acid
through glycolysis, rather than to produce energy through
mitochondrial oxidative phosphorylation, and help tumor cells to
survive in low glucose and low oxygen environments and facilitate
Table 3. Cofilin-1 immunostaining results of patients with lung adenocarcinoma.
Tissue type Number Male Female Positive rate Intensity Staining Score
a,
Adjacent normal tissues 30 14 16 0.5360.73 0.5060.68 0.6760.99
Well 21 11 10 0.9060.77 0.8660.73 1.1461.06
Moderately 37 16 21 1.2160.79 1.6561.01 2.5862.26
Poorly 40 19 21 2.5360.64 2.5560.55 6.4362.12
a: Total staining of cofilin-1 was scored as the product of the staining intensity (on a scale of 0–3) 6the percentage of cells stained (on a scale of 0–3).
doi:10.1371/journal.pone.0027309.t003
Figure 4. Suppression of PKM2 showed significantly antitumor effects. (A). Flow cytometry assay. SPC-A1 cells treated with PKM2-ShRNA
plasmids for 48 h have a significantly sub-G1 peak compared with control groups. (B). Colony formation assay. Following transfection, SPC-A1 cells
were allowed to grow for additional 14 days. The colonies were then fixed with methanol and stained with Crystal Violet. (C). Clonogenic formation
assay showed that the clone numbers were 237624.78, 224621.61, 216614.09, and 8369.43 in PBS group, Lipo group, NC group, and PKM2-ShRNA
treated group, respectively. Inhibition ratio of PKM2-ShRNA group was 64.9% compared with PBS group (Dunnett-t test, P,0.01). (D). Expression of
PKM2 in SPC-A1 was significantly down-regulated by PKM2-ShRNA plasmids. (1) PBS group; (2) Lipo group; (3) NC group; (4) PKM2-ShRNA group.
doi:10.1371/journal.pone.0027309.g004
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numerous cancers including lung, gastric, cervical, colorectal
cancers [38,40-42]. Increasing studies has also shown that
inhibition of glycolysis signaling is a very promising approach for
cancer treatment [38,43]. However, no study has been performed
previously to assess if there were any correlations among PKM2
expression, histo-differentiation, and survival rate of lung adeno-
carcinoma and to examine if PKM2 can be used as an effective
target for lung cancer therapy. Our study showed that overex-
pression of PKM2 was correlated with a low degree of
differentiation, and survival analysis also displayed PKM2 could
be developed as an independent prognostic factor for lung
adenocarcinoma. And consistent with previous studies
[18,38,44], our results also showed that PKM2 silence alone can
retard tumor cell growth by inducing apoptosis and inhibiting
proliferation both in vitro and in vivo. Obviously, more extensive
investigations are required to elucidate the complex molecular
functions of PKM2 in lung adenocarcinoma.
Cofilin-1 is one of the main proteins in charge of cell motility
that is regulated by many factors such as phosphorylation, pH,
binding of phosphoinositides, and subcellular compartmentaliza-
tion. Local activation of cofilin-1 by uncaging induces lamellipod
formation and sets the direction of cell motility. The overexpres-
sion of cofilin can increase the velocity of cell migration in
dictyostelium [45] and in human glioblastoma cells [46]. The
spontaneous overexpression of cofilin has been detected in the
invasive subpopulation of tumor cells in mammary tumors [47]. In
the present study, cofilin-1 was found to be overexpessed in lung
Figure 5. Suppression of PKM2 showed antitumor effects in xenograft mice model. (A). Tumor volume growth curve and tumor weight
after caudal vein injection of PKM2-ShRNA plasmids complexed with cationic liposome (DOTAP/Chol). PKM2-ShRNA treatment resulted in
significantly decreased tumor growth, compared with control groups (P,0.05). (B&C ). TUNEL assay and PCNA IHC staining showed the average
percentage of PCNA- and TUNEL-positive-staining nuclei (counted in five random fields) were significantly lower (PCNA assay) or higher (TUNEL assay)
compaired with control groups (P,0.01).
doi:10.1371/journal.pone.0027309.g005
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with a low degree of differentiation. Furthermore, Kaplan-Meier
survival analysis showed that cofilin-1 could serve as an
independent prognostic factor for lung adenocarcinoma.
Moreover,theresultsfromthecombinationofPKM2and cofilin-
1 as predictor for survival showed that the 5-year overall survival
rate for the PKM2-/cofilin-1- strongly positive group was very poor
(0%), compared with the other two groups, which showed a
significantly better outcome. It has been accepted that single marker
will not havethe sensitivity and specificitynecessary tobe used onits
own for diagnosis/prognosis of tumors. The multiparametric
approach is likely to improve the sensitivity and specificity.
Considering the biological functions of cofilin-1 in cell motility,
we evaluated the effects of cofilin-1 silencing in lung cancer
metastases in vivo. Our results showed that cofilin-1-ShRNA
delayed tumor metastasis and prolonged mice survival obviously,
which suggested that cofilin-1 might serve as a potential target for
lung metastases therapy.
In conclusion, in the present study, we have found thirty two
differentially expressed proteins in human pulmonary adenocar-
cinoma using 2-DE-MS/MS proteomic methods. Pathological
analysis showed that PKM2 and cofilin-1 are promising diagnostic
and prognostic biomarkers for lung adenocarcinoma. Further in
vitro and in vivo analysis indicated that silencing of PKM2 or
cofilin-1 showed significantly antitumor effects, suggesting that
both of them may serve as potential therapeutic targets for
pulmonary adenocarcinoma.
Supporting Information
Table S1 Identified proteins by MS/MS analysis.
(DOC)
Figure 6. Cofilin-1 suppression retarded pulmonary metastatic tumor growth and enhanced mice survival. (A). Representative photos
of metastatic-tumor-bearing lung tissues (B). Lung weight changes of mice treated with cofilin-1-ShRNA (P,0.05). (C). Kaplan-Meier survival curves of
tumor-bearing mice (Log-rank test, P,0.01). (D). Treatment with PKM2 or cofilin-1-ShRNA did not affect the growth of normal human bronchial
epithelial cells BEAS-2B by clonogenic formation assays (P.0.05). (E). In vivo studies showed that the lung weight of PKM2 or cofilin-1-ShRNA treated
group (normal mice, i.e. not bearing tumor) did not have significant changes compared with the control groups (P.0.05).
doi:10.1371/journal.pone.0027309.g006
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